Merck cholesterol drug fails; risks seen/ But yet approved in the European Union in since 2008
Merck & Co's Tredaptive failed in a major trial, showing no benefit over statins and increased side effects. Merck will not seek U.S. approval and advises against new prescriptions. Shares fell 2.5% to $42.56. Tredaptive had $13M sales in 2012, with potential $300M global sales forecast if successful. Analysts suggest it may be removed from overseas markets.
How this was made
The 30-second read
Why it matters
The trial failure eliminates a major US launch opportunity, reducing future revenue potential and affecting Merck's lipid‑therapy pipeline.
Market read
Merck stock fell 2.5% on the news; investors will reassess exposure to HDL‑raising therapies.
What to watch
Potential revenue from existing EU sales ($13 M) and pipeline diversification could cushion impact.
Background
Merck's Tredaptive combined niacin with laropiprant to raise HDL while reducing flushing. The HPS2‑THRIVE trial enrolled >25,000 patients over four years.
Ticker impact
Merck announced its Tredaptive trial failed safety and efficacy endpoints and will not seek US approval, causing a 2.5% share drop.
Short-term downside pressure; potential further decline if no alternative pipeline news.
The trial failure is a primary disclosure for a large‑cap pharma; shares already fell 2.5% on the news.
Market effects
HDL‑raising drug sector faces heightened scrutiny; competitors may see short‑term rally.
US pharma stocks could see modest pullback; European markets less affected as drug remains approved there.
Limited to Merck and similar lipid‑therapy developers.
Counterpoint
If Merck's alternative CETP inhibitor anacetrapib succeeds, the setback may be temporary.
Key entities
- companyMerck & Co., Inc.
Pharmaceutical company conducting the failed trial.
- productTredaptive
Experimental HDL‑raising drug that failed the trial.
